INTRODUCTION AND OBJECTIVES: Partial nephrectomy is widely utilized for surgical management of small renal masses. Robotic partial nephrectomy (RPN) has demonstrated improved postoperative morbidity and comparable oncologic outcomes compared to open partial nephrectomy (OPN). However, there is limited data regarding the utilization of RPN across different socio-economic strata and racial groups in the United States. We investigated trends and disparities in utilization of RPN for management of cT1 and cT2 renal masses.
INTRODUCTION AND OBJECTIVES: Partial nephrectomy is widely utilized for surgical management of small renal masses. Robotic partial nephrectomy (RPN) has demonstrated improved postoperative morbidity and comparable oncologic outcomes compared to open partial nephrectomy (OPN). However, there is limited data regarding the utilization of RPN across different socio-economic strata and racial groups in the United States. We investigated trends and disparities in utilization of RPN for management of cT1 and cT2 renal masses.
METHODS: Patients who underwent RPN and OPN for clinical stage T1 and T2, N0, M0 renal masses from 2010 to 2013 were identified in the National Cancer Data Base (NCDB). Univariate and multivariable logistic regression analyses were performed to evaluate differences in receiving RPN across various patient groups.
RESULTS: A total of 23,681 patients fulfilled inclusion criteria. Utilization of RPN for management of cT1/cT2 renal masses significantly increased from 2010 to 2013 compared to OPN (Figure.1) . Black (aOR¼0.91, 95%CI: 0.84-0.99) and Hispanic (aOR¼0.85, 95% CI: 0.76-0.94) patients were less likely to undergo RPN in favor of OPN. RPN was less likely to be performed in rural counties (aOR¼ 0.81, 95% CI: 0.66-0.98) and in patients with no insurance (aOR¼0.52, 95% CI: 0.45-0.61) or patients covered by Medicaid (aOR¼0.81, CI: 0.73-0.89). No significant difference was seen with respect to utilization of RPN between academic and non-academic facilities. Patients with higher clinical stage and co-morbidities were also less likely to undergo RPN (aOR¼0.23, 95% CI: 0.15-0.36 and 0.79, 95% CI: 0.71-0.87 respectively).
CONCLUSIONS: Utilization of RPN continues to increase over time; however, there is significant disparity in utilization of RPN based on socio-economic status and race. Black or Hispanic patients and patients in rural communities and with limited insurance were more likely to be treated with OPN instead of RPN. INTRODUCTION AND OBJECTIVES: Bulb suction drain placement is routinely done following robotic-assisted partial nephrectomy secondary to concern for post-operative urine leak. We explore the necessity of bulb suction drain placement and the rate of postoperative urine leaks in patients who underwent robotic-assisted partial nephrectomy at our institution.
Source of
METHODS: We performed a retrospective chart review to analyze the occurrence of urine leaks following robotic-assisted partial nephrectomy performed by two fellowship trained surgeons between January 2012 to July 2016. Urine leak was defined as drain body fluid creatinine to serum creatinine ratio greater than 5 or any patient with symptomatic urinary ascites within 90 days post-operatively.
RESULTS: Our review included 208 patients who underwent robotic-assisted partial nephrectomy. A total of 124 patients had intraoperative 10 French bulb suction drain placement and 84 patients had drain placement omitted. The mean length of stay for patients who had drain placement versus those who did not was 3.0 and 2.4 days, respectively. In patients who had bulb suction drains, the mean duration the drain was left in place and drain output was 1.7 days and 180.2 mL, respectively. On post-operative day 1, drain-fluid creatinine (ng/dL) was measured, resulting in a mean drain-fluid creatinine to serum creatinine ratio of 0.97 (range 0.73-3.12). The mean tumor size (cm) and R.E.N.A.L. nephrometry score (range score 4-12) in patients with drain placement vs. those without was 3.3, 5.9 and 2.7, 5.2, respectively. There was a statistically significant difference (p¼ .007) in R.E.N.A.L. score between the two groups, but was ultimately inconsequential in our population. The collecting system was entered in 61 patients (29.3% of cases) resulting in zero urine leaks within this subgroup. No patients were re-admitted 30 to 90 days post-operatively for symptomatic urinary ascites or related complications.
CONCLUSIONS: Routine bulb suction drain placement, even in the event of collecting system entry, can safely be omitted following robotic-assisted partial nephrectomy. INTRODUCTION AND OBJECTIVES: Radical nephroureterectomy (RNU) with excision of a bladder cuff remains the standard treatment for upper tract urothelial carcinoma (UTUC). However, the approach to surgical excision of the distal ureter remains understudied with studies reporting conflicting results. Herein, we report oncologic outcomes for two approaches to resection of the distal ureter using a large single-center database.
METHODS: We reviewed 372 patients treated with RNU for UTUC who underwent intra-or extravesical bladder cuff excision from 1995 to 2009. Intravesical excision was defined as a separate anterior cystotomy with circumferential excision of the distal ureter, while extravesical excision was a lateral cystotomy encompassing the ipsilateral ureteral orifice. Patients with metastatic disease at RNU, neoadjuvant chemotherapy, and non-urothelial primary were excluded. Multivariable Cox regression analysis was performed to evaluate Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1275 characteristics associated with patients' risk of cancer-specific mortality (CSM). Kaplan-Meier analysis was used to evaluate recurrence free survival (RFS). RESULTS: Median patient age at RNU was 73.7 years (IQR 65.4, 79.5); 67% (n¼249) were male and 64% (n¼238) underwent extravesical excision. Median follow-up was 47 months (IQR 16.4, 101.4) , during which time 52.4% (n¼195) experienced a bladder or systemic recurrence and 17.5% (n¼65) died due to metastatic urothelial carcinoma. There was no statistically significant difference for 5-year RFS between the two groups (p¼0.29). On multivariable analysis features independently associated with increased risk of CSM included smoking history (HR 2.31; p¼0.03), high grade (HR 4.23; p<0.001), pT2 or higher (HR 2.51; p¼0.01), lymph node positive disease(HR 4.29; p<0.01) and tumor size > 3 cm (HR 2.10; p¼0.02). Importantly, approach to the bladder cuff excision was not associated with an increased risk of disease recurrence (HR¼1.11; p¼0.60) or CSM (HR 1.26; p¼0.52).
CONCLUSIONS: Excision of the entire ureter, including the intramural component, is an important part of RNU. However, intra-or extravesical approach to the distal ureter, does not affect RFS or CSM. Therefore, our data validates the oncologic safety of both approaches to the bladder cuff for patients undergoing RNU for UTUC.
Source of Funding: None

PD66-12 OUTCOMES ON ILEAL MUCOSAL CUFF MANAGEMENT DURING RADICAL NEPHROURETERECTOMY
Amir Toussi*, Vidit Sharma, Tanner Miest, George Chow, Bradley Leibovich, Matthew Tollefson, Rochester, MN INTRODUCTION AND OBJECTIVES: Patients who undergo radical cystectomy for urothelial cancer are at risk for upper tract urothelial carcinoma (UTUC). It is well-accepted that the removal of a formal bladder cuff at the time of radical nephroureterectomy (RNU) results in improved oncologic outcomes. However, the effects of ileal mucosal cuff excision in patients undergoing RNU who have had a prior urinary diversion has not been studied. To our knowledge, we present the first report on outcomes of ileal mucosal cuff management for patients undergoing RNU for UTUC.
METHODS: Between 1995 and 2009 we retrospectively reviewed 483 patients at Mayo Clinic who underwent RNU for primary UTUC. We identified 41 patients who underwent RNU after having a previous radical cystectomy. Patients with mucosal cuff excision identified pathologically were analyzed and compared to those without a mucosal cuff. Kaplan Meier analyses were used to estimate recurrence free survival.
RESULTS: Median age of the cohort was 72 (IQR 66, 77) and 32 (78%) were male. A total of 18 (43.9%) patients underwent ileal cuff excision. Tumor multifocality, non-muscle invasive tumors (<pT1), and ureteral tumors were seen more frequently in patients who underwent cuff excision. Between the two groups there was no significant difference in intra-operative, 5 (27.8%) cuff vs. 6 (26.0%) no cuff, or postoperative complications, 4 (23.5%) vs. 8 (44.4%) no cuff (p¼0.90 and p¼0.19; respectively). At a median follow up of 47 months, there was no significant difference in 4-year recurrence free survival between the mucosal cuff excision and no mucosal cuff groups (20.4% vs. 30.4%; p¼0.61). Moreover, the rate of recurrence in the ileal conduit was comparable between the two groups, 1 (5.5%) cuff vs 3 (13%) no cuff (p¼0.41).
CONCLUSIONS: We found no significant difference in oncologic outcomes between patients with ileal mucosal cuff excision and those without a mucosal cuff at the time of RNU. Furthermore, there was no significant increase in intra-or post-operative complications by removing the mucosal cuff. In well-selected patients, oncologic outcomes may not be compromised by lack of ileal cuff excision. is arguably a valid option for management of bladder cancer in selected cases. The majority of reported studies however have short term follow up as well as small sample size. We aimed to evaluate retrospectively our long term experience of prostate sparing cystectomy and compare it with our results of nerve sparing cystoprostatectomy (NSCP) in the laparoscopic/robotic era METHODS: Between 2001 and 2011, 60 patients were treated with laparoscopic or robotic PSC for muscle invasive or recurrent non muscle invasive bladder cancer. These patients were matched and compared to 47 patients who received laparoscopic or robotic NSCP and orthotopic bladder substitution during the same study period. Regarding continence, surviving patients were postoperatively contacted, at 3 months and 1 year, to answer a questionnaire based on the International Continence Society guidelines for reporting continence after urinary diversion. Potency was accessed by a house made questionnaire addressing the use of any medications or devices to achieve erection.
Source of Funding: None
RESULTS: Mean patient age was 60.35 and 62.12 for PSC and NSCP respectively. Median follow up was 69.5 months and 62 months for PSC and NSCP respectively. Forty percent of PSC had ¼ pT1N0, 30% pT2N0, 22% ¼ pT3N0 while 8% had N+ disease; compared to NSCP patients whom 38% had ¼pT1N0, 19% pT2N0, 23% ¼ pT3N0 and 19% N+. (p¼0.74) The overall 3-and 5-year cancer specific survivals were 92% and 90% in the PSC group, and 82% and 79% in the NSCP group respectively. The local recurrence rates were 11.7 % and 21.3 % for the PSC and the NSCP groups respectively, and the respective distant recurrence rate was 17% and 28%. Regarding continence; 45% in the PSC showed immediate and full recovery of continence day and night compared to no patient in the NSCP group.
After 1 year, 97% and 71% of PSC group were completely leak-free for day and night respectively, compared to 78% and 37% in NSCP (p¼0.001). The incidence of self catheterization was equal in both groups at 15%. On long term follow up, 42% of PSC patients developed symptoms secondary to outlet obstruction and 18% of them required endoscopic resection of their prostate. While in NSCP patients, 4% developed anastomotic stricture that required endoscopic fulgration (p¼0.001) Regarding potency; 49% of PSC and 23% of NSCP reported maintaining similar preoperative potency level. Sexual intercourse was achievable without any treatment in 68% of PSC compared to 37% in NSCP. The incidence of intracavernosal injection was higher in the NSCP arm compared to the PSC (41% vs.17%) Four patients (9%) in the NSCP group failed all conservative management and required penile prosthesis compared to no patient in the PSC group. ( p¼0.001) CONCLUSIONS: Prostate sparing cystectomy is superior to nerve-sparing cystoprostatectomy regarding continence and potency. However, candidate patients who wish to retain their prostate should be informed about the long term need to manage outflow obstructive symptoms.
